Sugi Predict

Sugi Predict / Compounds / SCHEMBL2936089

SCHEMBL2936089

SCHEMBL2936089

CC1C(=O)N(c2ccc(OC(F)(F)F)cc2)C(=O)N1Cc1ccncc1N1CCOCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 1/20 0.41
▸ GAA P10253 2/20 0.37
▸ MAPT P10636 2/20 0.37
▸ PRKDC P78527 1/20 0.36
▸ ALDH1A1 P00352 4/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ ABL1 P00519 1/20 0.35
▸ SMO Q99835 2/20 0.35
▸ SCN10A Q9Y5Y9 2/20 0.35
▸ SCN2A Q99250 1/20 0.35
▸ TEAD1 P28347 2/20 0.34
▸ AKT1 P31749 1/20 0.34
▸ PIK3CA P42336 1/20 0.34
▸ MTOR P42345 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ GLA P06280 1/20 0.34
▸ LCK P06239 1/20 0.34
▸ HCRTR1 O43613 1/20 0.33
▸ HCRTR2 O43614 1/20 0.33
▸ GPR139 Q6DWJ6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2939878 0.91 IGF1R (0.42) IGF1RGAAMAPTSMOHCRTR1
SCHEMBL2941193 0.90 IGF1R (0.42) IGF1RALDH1A1SMOHCRTR1HCRTR2
SCHEMBL2937002 0.86 IGF1R (0.41) IGF1RSMOSCN10AHCRTR1HCRTR2
SCHEMBL2937913 0.85 IGF1R (0.59) IGF1RMAPTSMOSCN10ATEAD1
SCHEMBL2940895 0.85 EPHX2 (0.39) IGF1RGAAALDH1A1HSD17B10ABL1
SCHEMBL2941512 0.83 IGF1R (0.41) IGF1RSMOTEAD1AKT1PIK3CA
SCHEMBL2938066 0.83 IGF1R (0.39) IGF1RGAAMAPTALDH1A1HSD17B10
SCHEMBL2938341 0.82 IGF1R (0.46) IGF1RSMOHCRTR1HCRTR2
SCHEMBL2942595 0.82 IGF1R (0.46) IGF1RSMOHCRTR1HCRTR2
SCHEMBL2941220 0.82 IGF1R (0.46) IGF1RSMOHCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 — — US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 — — EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 — — US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 — — US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 IGF1R 1595/4885GAA 1964/4885MAPT 1554/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA IGF1R 962/4885GAA 2768/4885MAPT 2136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.